Genetic alterations and oncogenic pathways in hepatocellular carcinoma

Annals of the New York Academy of Sciences

Volumn 963, Issue , 2002, Pages 21-36

  Lévy, Laurence ^a   Renard, Claire Angélique ^a   Wei, Yu ^a   Buendia, Marie Annick ^a  

^a INSTITUT PASTEUR   (France)

Author keywords

Beta catenin; CGH; Comparative genomic hybridization; Hepatitis virus; Hepatocellular carcinoma; LOH; Loss of heterozygosity

Indexed keywords

AFLATOXIN B1; BETA CATENIN; CYCLIN D1; PROTEIN P53;

ALCOHOL ABUSE; ALLELISM; CHROMOSOME ANALYSIS; CONFERENCE PAPER; DIET; GENE DELETION; GENE DISRUPTION; GENE INACTIVATION; GENE LOCATION; GENE MUTATION; HEPATITIS B; HEPATITIS C; LIVER CANCER; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; MALIGNANT TRANSFORMATION; ONCOGENE; PROGNOSIS; RISK FACTOR; TUMOR SUPPRESSOR GENE;

HEPATITIS B VIRUS; HEPATITIS C VIRUS;

EID: 0036291010     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2002.tb04091.x     Document Type: Conference Paper

References (112)

1. Global epidemiology of hepatocellular carcinoma
2. Mortality by cause for eight regions of the world: Global burden of disease study
3. Impact of HBV, HCV, and GBVC/HGV on hepatocellular carcinomas in Europe: Results of an European concerted action
4. High incidence of hepatitis B virus infections among chronic hepatitis cases of unknown etiology
5. Molecular bases for the development of hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC)
6. Immune pathogenesis of hepatocellular carcinoma
7. The woodchuck hepatitis virus X gene is important for establishment of virus infection in woodchucks
8. Woodchuck hepatitis virus X protein is required for viral infection in vivo
9. Trans-activation of cellular genes by hepatitis virus proteins: A possible mechanism of hepatocarcinogenesis
10. The transcriptional function of the hepatitis B virus X protein and its role in hepatocarcinogenesis
11. Hepatitis B virus transactivator protein X interacts with the TATA-binding protein
12. Human RPB5, a subunit shared by eukaryotic nuclear RNA polymerases, binds human hepatitis B virus X-protein and may play a role in X transactivation
13. Hepatitis B virus pX targets TFIIB in transcription coactivation
14. Src kinases involved in hepatitis B virus replication
15. Transactivation by hepatitis B virus X protein is promiscuous and dependent on mitogen-activated cellular serine/threonine kinases
16. Ras- and Raf-dependent activation of c-Jun transcriptional activity by the hepatitis B virus transactivator pX
17. Hepatitis B virus HBx protein activates Ras-GTP complex formation and establishes a Ras, Raf, MAP kinase signaling cascade
18. Hepatitis B virus HBx protein activates transcription factor NF-KB by acting on multiple cytoplasmic inhibitors of rel-related proteins
19. Hepatitis B virus HBx protein sensitizes cells to apoptotic killing by tumor necrosis alpha
20. The hepatitis B virus X protein activates nuclear factor of activated T cells (NF-AT) by a cyclosporin A-sesitive pathway
21. The hepatitis B virus X protein up-regulates tumor necrosis factor alpha gene expression in hepatocyte
22. Direct association and nuclear import of the hepatitis B virus X protein with the NF-kappaB inhibitor IkappaBalpha
23. Expression of hepatitis B virus X protein in HBV-infected human livers and hepatocellular carcinoma
24. Selective accumulation of the X transcript of hepatitis B virus in patients negative for hepatitis B surface antigen with hepatocellular carcinoma
25. Hepatitis B virus X mutants, present in hepatocellular carcinoma tissue abrogate both the antiproliferative and transactivation effects of HBx
26. Hepnavirus integration generates virus-cell cotranscripts carrying 3′ truncated X genes in human and woodchuck liver tumors
27. A transactivating function encoded in the hepatitis B virus X gene is conserved in the integrated state
28. HBx gene of hepatitis B virus induces liver cancer in transgenic mice
29. Woodchuck hepatitis virus X protein is present in chronically infected woodchuck liver and in woodchuck hepatocellular carcinomas which are permissive for viral replication
30. Increased sensitivity to the hepatocarcinogen diethylnitrosamine in transgenic mice carrying the hepatitis B virus x gene
31. The hepatitis B virus X gene potentiates c-myc-induced liver oncogenesis in transgenic mice
32. Malignant transformation of immortalized transgenic hepatocytes after transfection with hepatitis B virus DNA
33. Hepatitis B virus X protein transcription activation domains are neither required nor sufficient for cell transformation
34. Hepatitis B virus HBx protein deregulates cell cycle checkpoint controls
35. The hepatitis B virus X gene induces p53-mediated programmed cell death
36. Hepatitis B virus X protein and p53 tumor suppressor interactions in the modulation of apoptosis
37. Hepatitis B virus X protein interacts with a probable DNA repair protein
38. Interaction of the UV-damaged DNA-binding protein with hepatitis B virus X protein is conserved among mammalian hepadnaviruses and restricted to transactivation-proficient X-insertion mutants
39. Cytosol is the prime compartment of hepatitis B virus X protein where it colocalizes with the proteasome
40. Hepatitis B virus X protein is both a substrate and a potential inhibitor of the proteasome complex
41. Hepatitis B x antigen and p53 are associated in vitro and in liver tissues from patients with primary hepatocellular carcinoma
42. Functional inactivation but not structural mutation of p53 causes liver cancer
43. The transactivation and p53-interacting functions of hepatitis B virus X protein are mutually interfering but distinct
44. Hepatitis B virus X protein interferes with cellular DNA repair
45. Expression of hepatitis B virus X protein does not alter the accumulation of spontaneous mutations in transgenic mice
46. The hepatitis B virus encoded oncoprotein pX amplifies TGF-beta family signaling through direct interaction with Smad4: Potential mechanism of hepatitis B virus-induced liver fibrosis
47. Role of NF-kappaB and myc proteins in apoptosis induced by hepatitis B virus HBx protein
48. Association of hepatitis B virus X protein with mitochondria causes mitochondrial aggregation at the nuclear periphery, leading to cell death
49. Abrogation of p53-induced apoptosis by the hepatitis B virus X gene
50. Transcriptional repression of the human p53 gene by hepatitis B viral X protein
51. Activation of Src family kinases by hepatitis B virus HBx protein and coupled signaling to Ras
52. X-gene product of hepatitis B virus induces apoptosis in liver cells
53. Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand-expressing tumor cells: A mechanism of immune evasion?
54. Identification and characterization of a prevalent hepatitis B virus X protein mutant in taiwanese patients with hepatocellular carcinoma
55. A genetic model for colorectal tumorigenesis
56. The hallmarks of cancer
57. Frequent rearrangements of chromosomes 1, 7, and 8 in primary liver cancer
58. Abnormalities of chromosome 1 and loss of heterozygosity on 1p in primary hepatomas
59. Oncogenes, tumor suppressors and co-factors in hepatocellular carcinoma
60. Genetics of hepatocellular carcinoma
61. Comprehensive allelotyping of human hepatocellular carcinoma
62. Concerted nonsyntenic allelic losses in hyperploid hepatocellular carcinoma as determined by a high-resolution allelotype
63. M6P/IGF2R gene is mutated in human hepatocellular carcinomas with loss of heterozygosity
64. Aberrations of the tumor suppressor p53 and retinoblastoma genes in human hepatocellular carcinomas
65. AXIN1 mutations in hepatocellular carcinomas, and growth suppression in cancer cells by virus-mediated transfer of AXIN1
66. Accumulation of genetic changes during development and progression of hepatocellular carcinoma: Loss of heterozygosity of chromosome arm 1p occurs at an early stage of hepatocarcinogenesis
67. Chromosomal abnormality in hepatocellular carcinoma by comparative genomic hybridisation in Taiwan
68. Loss of heterozygosity and microsatellite instability in hepatocellular carcinoma in Taiwan
69. Identification of three distinct regions of allelic deletions on the short arm of chromosome 8 in hepatocellular carcinoma
70. Recurrent chromosomal abnormalities in hepatocellular carcinoma detected by comparative genomic hybridization
71. Genetic aberrations detected by comparative genomic hybridization in hepatocellular carcinomas: Their relationship to clinicopathological features
72. Chromosomal aberrations in human hepatocellular carcinomas associated with hepatitis C virus infection detected by comparative genomic hybridization
73. Assessment of genetic changes in hepatocellular carcinoma by comparative genomic hybridization analysis: Relationship to disease stage, tumor size, and cirrhosis
74. Genetic instabilities in human cancers
75. Microsatellite instability associated with hepatocarcinogenesis
76. Microsatellite instability in European hepatocellular carcinoma
77. Mutations in the APC tumour suppressor gene cause chromosomal instability
78. Chromosome abnormalities in peripheral blood cells of hepatitis B virus chronic carriers
79. Accumulation of genetic alterations in a human hepatoma cell line transfected with hepatitis B virus
80. Extensive analysis of duplicated-inverted hepatitis B virus integrations in human hepatocellular carcinoma
81. p53, the cellular gatekeeper for growth and division
82. p53 gene abnormalities are closely related to hepatoviral infections and occur at a late stage of hepatocarcinogenesis
83. Selective G to T mutations of p53 gene in hepatocellular carcinoma from southern Africa
84. Mutational hotspot in the p53 gene in human hepatocellular carcinomas
85. Aflatoxin B1 induces the transversion of G-->T in codon 249 of the p53 tumor suppressor gene in human hepatocytes
86. RB tumor suppressor gene expression in hepatocellular carcinoma from patients infected with the hepatitis B virus
87. Mutation analysis of transforming growth factor beta type II receptor, Smad2, and Smad4 in hepatocellular carcinoma
88. Smad2 and Smad4 gene mutations in hepatocellular carcinoma
89. Reduced stability of retinoblastoma protein by gankyrin, an oncogenic ankyrin-repeat protein overexpressed in hepatomas
90. Frequent loss of heterozygosity on 6q at the mannose 6-phosphate/insulin-like growth factor II receptor locus in human hepatocellular tumors
91. Failure to detect genetic alteration of the mannose-6-phosphate/insulin-like growth factor 2 receptor (M6P/IGF2R) gene in hepatocellular carcinomas in Japan
92. Axin, an inhibitor of the Wnt signalling pathway, interacts with beta-catenin, GSK-3beta and APC and reduces the beta-catenin level
93. Cadherin-catenin complex: Protein interactions and their implications for cadherin function
94. Wnt signaling: A common theme in animal development
95. The adenomatous polyposis coli (APC) tumor suppressor
96. TCF/LEF factor earn their wings
97. Identification of c-MYC as a target of the APC pathway
98. Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells
99. The oncogenic activation of beta-catenin
100. Somatic mutations of the beta-catenin gene are frequent in mouse and human hepatocellular carcinomas
101. Frequent mutations in the beta-catenin gene in desmoid tumors from patients without familial adenomatous polyposis
102. Close correlation between beta-catenin gene alterations and nuclear accumulation of the protein in human hepatocellular carcinomas
103. Nuclear accumulation of mutated beta-catenin in hepatocellular carcinoma is associated with increased cell proliferation
104. Beta-catenin mutations are frequent in human hepatocellular carcinomas associated with hepatitis C virus infection
105. Beta-catenin mutations in hepatocellular carcinoma correlate with a low rate of loss of heterozygosity
106. Beta-catenin mutations are associated with a subset of low-stage hepatocellular carcinoma negative for hepatitis B virus and with favorable prognosis
107. Mutation of beta-catenin is an early event in chemically induced mouse hepatocellular carcinogenesis
108. Hepatocellular carcinoma in WHV/N-myc2 transgenic mice: Oncogenic mutations of beta-catenin and synergistic effects of p53-null alleles
109. Distinct chromosomal abnormality pattern in primary liver cancer of non-B, non-C patients
110. Identification of differentially expressed genes in hepatocellular carcinoma with cDNA microarrays
111. Differential gene expression between chronic hepatitis B and C hepatic lesion
112. Genome-wide analysis of gene expression in human hepatocellular carcinomas using cDNA microarray: Identification of genes involved in viral carcinogenesis and tumor progression